Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically eval...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037020305237 |
id |
doaj-7689c3ac7ec94ebb9f06d51993558b03 |
---|---|
record_format |
Article |
spelling |
doaj-7689c3ac7ec94ebb9f06d51993558b032020-12-17T04:47:52ZengElsevierComputational and Structural Biotechnology Journal2001-03702021-01-0119115Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analysesGuobing Li0Shasha Ruan1Xiaolu Zhao2Qi Liu3Yali Dou4Fengbiao Mao5Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USADepartment of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China; The First Clinical College of Wuhan University, Wuhan, Hubei 430060, ChinaCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USADepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Corresponding authors at: Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China; Corresponding authors at: Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically evaluated the effect of SARS-CoV-2 on gene expression of both lung tissue and blood from COVID-19 patients using transcriptome profiling. Differential gene expression analysis revealed potential core mechanism of COVID-19-induced pneumonia in which IFN-α, IFN-β, IFN-γ, TNF and IL6 triggered cytokine storm mediated by neutrophil, macrophage, B and DC cells. Weighted gene correlation network analysis identified two gene modules that are highly correlated with clinical traits of COVID-19 patients, and confirmed that over-activation of immune system-mediated cytokine release syndrome is the underlying pathogenic mechanism for acute phase of COVID-19 infection. It suggested that anti-inflammatory therapies may be promising regimens for COVID-19 patients. Furthermore, drug repurposing analysis of thousands of drugs revealed that TNFα inhibitor etanercept and γ-aminobutyric acid-B receptor (GABABR) agonist baclofen showed most significant reversal power to COVID-19 gene signature, so we are highly optimistic about their clinical use for COVID-19 treatment. In addition, our results suggested that adalimumab, tocilizumab, rituximab and glucocorticoids may also have beneficial effects in restoring normal transcriptome, but not chloroquine, hydroxychloroquine or interferons. Controlled clinical trials of these candidate drugs are needed in search of effective COVID-19 treatment in current crisis.http://www.sciencedirect.com/science/article/pii/S2001037020305237 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guobing Li Shasha Ruan Xiaolu Zhao Qi Liu Yali Dou Fengbiao Mao |
spellingShingle |
Guobing Li Shasha Ruan Xiaolu Zhao Qi Liu Yali Dou Fengbiao Mao Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses Computational and Structural Biotechnology Journal |
author_facet |
Guobing Li Shasha Ruan Xiaolu Zhao Qi Liu Yali Dou Fengbiao Mao |
author_sort |
Guobing Li |
title |
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses |
title_short |
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses |
title_full |
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses |
title_fullStr |
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses |
title_full_unstemmed |
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses |
title_sort |
transcriptomic signatures and repurposing drugs for covid-19 patients: findings of bioinformatics analyses |
publisher |
Elsevier |
series |
Computational and Structural Biotechnology Journal |
issn |
2001-0370 |
publishDate |
2021-01-01 |
description |
The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically evaluated the effect of SARS-CoV-2 on gene expression of both lung tissue and blood from COVID-19 patients using transcriptome profiling. Differential gene expression analysis revealed potential core mechanism of COVID-19-induced pneumonia in which IFN-α, IFN-β, IFN-γ, TNF and IL6 triggered cytokine storm mediated by neutrophil, macrophage, B and DC cells. Weighted gene correlation network analysis identified two gene modules that are highly correlated with clinical traits of COVID-19 patients, and confirmed that over-activation of immune system-mediated cytokine release syndrome is the underlying pathogenic mechanism for acute phase of COVID-19 infection. It suggested that anti-inflammatory therapies may be promising regimens for COVID-19 patients. Furthermore, drug repurposing analysis of thousands of drugs revealed that TNFα inhibitor etanercept and γ-aminobutyric acid-B receptor (GABABR) agonist baclofen showed most significant reversal power to COVID-19 gene signature, so we are highly optimistic about their clinical use for COVID-19 treatment. In addition, our results suggested that adalimumab, tocilizumab, rituximab and glucocorticoids may also have beneficial effects in restoring normal transcriptome, but not chloroquine, hydroxychloroquine or interferons. Controlled clinical trials of these candidate drugs are needed in search of effective COVID-19 treatment in current crisis. |
url |
http://www.sciencedirect.com/science/article/pii/S2001037020305237 |
work_keys_str_mv |
AT guobingli transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses AT shasharuan transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses AT xiaoluzhao transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses AT qiliu transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses AT yalidou transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses AT fengbiaomao transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses |
_version_ |
1724380437616263168 |